Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Sep 22, 2011

Premium

Mo Bio Laboratories this week launched the RTS DNase kit for removing contaminating genomic DNA from RNA preparations while protecting the RNA samples from damage during the DNase treatment process.

The kit includes the first room-temperature-stable DNase I enzyme, which eliminates concerns over freeze-thaw cycles that may decrease enzymatic activity. The kit also contains a highly specific resin that is used to bind and remove the RTS DNase enzyme and divalent cations from the reaction for optimal qPCR results, Mo Bio said.


Lucigen this week announced the release of Taq98 Hot Start 2X Master Mix.

This new DNA polymerase is ideal for customers seeking to amplify difficult DNA templates, including targets with greater than 70 percent GC content. The product combines Taq polymerase with a unique fusion protein that enhances DNA binding, as well as CleanAmp dNTPs from TriLink Biotechnologies.

The end result, the company said, is a highly robust polymerase in an easy-to-use master mix that avoids primer-dimers and other common PCR problems while amplifying template DNA sequences that are often difficult for competing PCR kits to amplify.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.